Researchers aimed at reporting on the long-term evolution of estimated glomerular filtration rate (eGFR) in patients receiving antiviral treatment for hepatitis C virus (HCV).

• This cohort study involved a total of 1,987 patients with eGFR ≥ 15 mL/min/1.73m² who received interferon (IFN) or direct-acting antiviral (DAA) treatment.

• From the time point of sustained virologic response (SVR₁₂), biannual assessment of the eGFR was performed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

• Patients who achieved SVR₁₂ with anti-HCV treatment had significantly improved long-term eGFR evolution and risk of ESRD.

• Among patients who achieved SVR₁₂, there was comparable eGFR evolution in those treated with IFN or DAA.